Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia

References

• Bukelo MJ, Kanchan T, Unnikrishnan B, et al. Study of finger print patterns in children with acute lymphoblastic leukemia. Forensic Sci Med Pathol. 2011;7:21–25.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.
   PubMed Web of Science ®Google Scholar
• Kamel AM, Ebid GT, Moussa HS. N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia. Tumor Biol. 2015;36:6341–6348.
   PubMedGoogle Scholar
• Estey EH, Appelbaum FR. Leukemia and related disorders: integrated treatment approaches. New York (NY): Springer Science & Business Media; 2011.
   Google Scholar
• Dorantes-Acosta E, Zapata-Tarrés M, Miranda-Lora A, et al. Comparación de las características clínicas al diagnóstico de niños con leucemia linfoblástica aguda afiliados al Seguro Popular, con respecto al desenlace. Boletín Médico Del Hospital Infantil De México. 2012;69:190–196.
   Google Scholar
• Rivera-Luna R, Cárdenas-Cardos R, Olaya-Vargas A, et al. El niño de población abierta con cáncer en México. Consideraciones epidemiológicas. An Med (Mex). 2015;60:91–97.
   Google Scholar
• Reaman GH, Smith FO. Childhood leukemia: a practical handbook. New York (NY): Springer Science & Business Media; 2011.
   Google Scholar
• Sinnett D, Labuda D, Krajinovic M. Challenges identifying genetic determinants of pediatric cancers–the childhood leukemia experience. Familial Cancer. 2006;5:35–47.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Richer C, Sinnett H, et al. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev. 2000;9:557–562.
   PubMed Web of Science ®Google Scholar
• Vineis P, Veglia F, Garte S, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol. 2007;18:1230–1242.
   PubMed Web of Science ®Google Scholar
• Gra O, Glotov A, Kozhekbayeva ZM, et al. Genetic polymorphism of GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. Mol Biol. 2008;42:187–197.
   Web of Science ®Google Scholar
• Zanrosso CW, Emerenciano M, Faro A, et al. Genetic variability in N-acetyltransferase 2 gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil. Leuk Lymph. 2012;53:323–327.
   PubMed Web of Science ®Google Scholar
• Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol. 2007;166:741–751.
   PubMed Web of Science ®Google Scholar
• Jančová P, Šiller M. Phase II Drug metabolism. Topics on drug metabolism. Rijeka: InTech; 2012. p. 35–60.
   Google Scholar
• Gu J, Liang D, Wang Y, et al. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res/Gene Toxicol Environ Mutagen. 2005;581:97–104.
   PubMed Web of Science ®Google Scholar
• Dupret J-M, Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr Med Chem. 2005;12:311–318.
   PubMed Web of Science ®Google Scholar
• Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis. 2005;27:103–111.
   PubMed Web of Science ®Google Scholar
• Díaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA, et al. Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis. Mol Med Report. 2008;1:875–879.
   PubMed Web of Science ®Google Scholar
• Taja-Chayeb L, Agúndez J, Miguez-Muñoz C, et al. Arylamine N-acetyltransferase 2 genotypes in a Mexican population. Genet Mol Res. 2012;11:1082–1092.
   PubMed Web of Science ®Google Scholar
• Ramos MA, Mares RE, Avalos ED, et al. Pharmacogenetic screening of N-acetyltransferase 2, thiopurine s-methyltransferase, and 5, 10-methylene-tetrahydrofolate reductase polymorphisms in Northwestern Mexicans. Genetic Testing Mol Biomark. 2011;15:351–355.
   PubMed Web of Science ®Google Scholar
• Salazar-González R, Gómez R, Romano-Moreno S, et al. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population. Mol Biol Rep. 2014;41:7833–7843.
   PubMed Web of Science ®Google Scholar
• EL CONSEJO DSG, INSTITUTOS L, SALUD PSE. PROTOCOLO DE LA ATENCIÓN PARA LEUCEMIA LINFOBLÁSTICA. GUÍA CLÍNICA Y ESQUEMA DE TRATAMIENTO.
   Google Scholar
• Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 2008;55:1–20.
   PubMed Web of Science ®Google Scholar
• Tovar CFL. Factores de pronóstico en leucemia linfoblástica aguda pediátrica: posibles marcadores moleculares. [Prognostic factors in acute lymphoblastic leukemia: possible molecular markers]. Rev Med Inv. 2015;3:85–91.
   Google Scholar
• Majumder M, Ghosh S, Roy B. Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer. Indian J Med Res. 2012;136:605.
   PubMed Web of Science ®Google Scholar
• Barrett J, Smith G, Waxman R, et al. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis. 2003;24:275–282.
   PubMed Web of Science ®Google Scholar
• Ng C-S, Hasnat A, Al Maruf A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol. 2014;70:1079–1086.
   PubMed Web of Science ®Google Scholar
• Podgorná E, Diallo I, Vangenot C, et al. Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa. BMC Evol Biol. 2015;15:1.
   PubMed Web of Science ®Google Scholar
• Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health, Part B. 2009;12:440–472.
   PubMed Web of Science ®Google Scholar
• Minchin RF, Butcher NJ. The role of lysine 100 in the binding of acetylcoenzyme A to human arylamine N-acetyltransferase 1: implications for other acetyltransferases. Biochem Pharmacol. 2015;94:195–202.
   PubMed Web of Science ®Google Scholar
• Jiao L, Doll MA, Hein DW, et al. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol Biomarker Prevent. 2007;16:2379–2386.
   PubMed Web of Science ®Google Scholar
• Lilla C, Verla TE, Risch A, et al. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarker Prevent. 2006;15:99–107.
   PubMed Web of Science ®Google Scholar
• Sharma S, Cao X, Wilkens LR, et al. Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19:1866–1870.
   PubMed Web of Science ®Google Scholar
• Minchin RF, Hanna PE, Dupret J-M, et al. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol. 2007;39:1999–2005.
   PubMed Web of Science ®Google Scholar
• Agudo A, Sala N, Pera G, et al. No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarker Prevent. 2006;15:1043–1045.
   PubMed Web of Science ®Google Scholar
• Butcher NJ, Minchin RF. Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev. 2012;64:147–165.
   PubMed Web of Science ®Google Scholar
• Selinski S, Blaszkewicz M, Ickstadt K, et al. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol. 2013;87:2129–2139.
   PubMed Web of Science ®Google Scholar